Healthcare Realty Trust Appoints Thomas N. Bohjalian to Board

Healthcare Realty Trust Incorporated (NYSE:HR) has appointed Thomas N. Bohjalian to its board of directors, effective June 25, 2024. Mr. Bohjalian, who has over 30 years of real estate and finance experience, has been appointed to the board's newly formed capital allocation committee.

Mr. Bohjalian has been a member of Apartment Income REIT Corporation's board of directors since December 2021, and is currently a senior real estate advisor to BeyondView. Previously, he spent 20 years at Cohen & Steers, where he was responsible for investment decisions for $40 billion of the firm's assets.

Knox Singleton, chairman of Healthcare Realty, stated, "We are pleased to welcome Tom to Healthcare Realty's board of directors. He is a highly respected leader in investment management with deep real estate expertise."

Todd Meredith, president and CEO of Healthcare Realty, commented, "Tom’s strong track record managing real estate investment funds will be invaluable as we continue to execute on our capital allocation priorities, gain operational momentum, and accelerate financial performance."

Healthcare Realty is a real estate investment trust (REIT) that owns and operates medical outpatient buildings primarily located around market-leading hospital campuses. The company's portfolio includes nearly 700 properties totaling over 40 million square feet concentrated in 15 growth markets.

In addition to the appointment of Mr. Bohjalian, Ferguson Partners advised the board of directors on this appointment.

For more information on Healthcare Realty, visit As a result of these announcements, the company's shares have moved 0.1% on the market, and are now trading at a price of $16.36. For the full picture, make sure to review Healthcare Realty Trust's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.